Kwansik Yoon

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

J. O’Shea, A. Milici, B. Reitz, 2003, Science.

Novel CCR1 antagonists with improved metabolic stability.

Christopher S. Poss, J. Kath, W. Brissette, 2004, Bioorganic & medicinal chemistry letters.

Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance.

R. Foti, M. Fisher, T. J. Strelevitz, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.

A. Kalgutkar, C. Gabel, R. Shepard, 2011, Bioorganic & medicinal chemistry letters.

PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy

L. Pustilnik, J. Christensen, B. D. Cohen, 2010, Molecular Cancer Therapeutics.

Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.

C. Gabel, R. Shepard, D. Perregaux, 2011, Bioorganic & medicinal chemistry letters.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

M. Huband, A. Marfat, J. Driscoll, 2013, Bioorganic & medicinal chemistry letters.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2017, Bioorganic & medicinal chemistry letters.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2013, Bioorganic & medicinal chemistry letters.